Skip to main content

Table 4 Treatment-related toxicity profiles

From: Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

  Afatinib Erlotinib p-value
  All grades (%) ≥Grade 3 (%) All grades (%) ≥Grade 3 (%) All grades ≥Grade 3
Rash 15 (60.0) 0 (0.0) 19 (67.9) 5 (17.9) 0.04 0.03
Diarrhea 15 (60.0) 7 (28.0) 3 (10.7) 1 (3.6) 0.002 0.01
Mucositis 1 (4.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.29 NA
Paronychia 2 (8.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.31 NA
Impaired liver function 6 (24.0) 0 (0.0) 1 (3.6) 0 (0.0) 0.02 NA
Hypokalemia 2 (8.0) 2 (8.0) 0 (0.0) 0 (0.0) 0.13 0.13
  1. Abbreviation: NA not applicable